Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481204 · ClinicalTrials.gov registry record · Phase 2
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
A Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT04481204: Active Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT04481204 is a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 105 participants, above the 36-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (192% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04481204, a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease. Each stage group will have a defined standard of care chemotherapy regimen for a control arm, serving as a basis of comparison. Each group may have one or more experimental arms. Experimental arms may be added to the platform over time, and the effects of the experimental treatments will be tested against the controls for each group.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Gemcitabine
- DRUG Irinotecan
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2027-04-06 |
| Phase | Phase 2 |
What the registry record for NCT04481204 still lists
NCT04481204 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 36-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (192% higher).
The record links to 3 conditions, with Borderline Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT04481204 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04481204 about?
NCT04481204 is a clinical study titled "New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study". This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease. Each stage group will have a defined standard of care chemotherapy regimen for a control arm, serving as...
What is the current status of trial NCT04481204?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2023-04-18. Estimated completion is 2027-04-06.
What conditions does trial NCT04481204 study?
This clinical trial studies the following conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT04481204?
The interventions under investigation include: Cisplatin (DRUG), Fluorouracil (DRUG), Leucovorin (DRUG), Gemcitabine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT04481204?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04481204 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Resectable Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI